Growth inhibition in head and neck cancer cell lines by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Cell survival is the result of a balance between programmed cell death and cellular proliferation. Cell membrane receptors and their associated signal transducing proteins control these processes. Of the numerous receptors and signaling proteins, epidermal growth factor receptor (EGFR) is one of the most important receptors involved in signaling pathways implicated in the proliferation and survival of cancer cells. EGFR is often highly expressed in human tumors including oral squamous cell carcinomas, and there is increasing evidence that high expression of EGFR is correlated with poor clinical outcome of common human cancers. Therefore, we examined the antiproliferative activity of gefitinib, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), in head and neck cancer cell lines. SCC-9, KB cells were cultured and growth inhibition activity of gefitinib was measured with MTT assay. To study influence of gefitinib in cell cycle, we performed cell cycle analysis with flow cytometry. Western blot was done to elucidate the expression of EGFR in cell lines and phosphorylation of EGFR and downstream kinase protein, Erk and Akt. Significant growth inhibition was observed in SCC-9 cells in contrast with KB cells. Also, flow cytometric analysis showed G1 phase arrest only in SCC-9 cells. In Western blot analysis for investigation of EGFR expression and downstream molecule phosphorylation, gefitinib suppressed phosphorylation of EGFR and downstream protein kinase Erk, Akt in SCC-9. However, in EGFR positive KB cells, weak expression of active form of Erk and Akt and no inhibitory activity of phosphorylation in Erk and Akt was observed. The antiproliferative activity of gefitinib was not correlated with EGFR expression and some possibility of phosphorylation of Erk and Akt as a predictive factor of gefitinib response was emerged. Further investigations on more reliable predictive factor indicating gefitinib response are awaited to be useful gefitinib treatment in head and neck cancer patients.
Abstract
Cell survival is the result of a balance between programmed cell death and cellular proliferation. Cell membrane receptors and their associated signal transducing proteins control these processes. Of the numerous receptors and signaling proteins, epidermal growth factor receptor (EGFR) is one of the most important receptors involved in signaling pathways implicated in the proliferation and survival of cancer cells. EGFR is often highly expressed in human tumors including oral squamous cell carcinomas, and there is increasing evidence that high expression of EGFR is correlated with poor clinical outcome of common human cancers. Therefore, we examined the antiproliferative activity of gefitinib, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), in head and neck cancer cell lines. SCC-9, KB cells were cultured and growth inhibition activity of gefitinib was measured with MTT assay. To study influence of gefitinib in cell cycle, we performed cell cycle analysis with flow cytometry. Western blot was done to elucidate the expression of EGFR in cell lines and phosphorylation of EGFR and downstream kinase protein, Erk and Akt. Significant growth inhibition was observed in SCC-9 cells in contrast with KB cells. Also, flow cytometric analysis showed G1 phase arrest only in SCC-9 cells. In Western blot analysis for investigation of EGFR expression and downstream molecule phosphorylation, gefitinib suppressed phosphorylation of EGFR and downstream protein kinase Erk, Akt in SCC-9. However, in EGFR positive KB cells, weak expression of active form of Erk and Akt and no inhibitory activity of phosphorylation in Erk and Akt was observed. The antiproliferative activity of gefitinib was not correlated with EGFR expression and some possibility of phosphorylation of Erk and Akt as a predictive factor of gefitinib response was emerged. Further investigations on more reliable predictive factor indicating gefitinib response are awaited to be useful gefitinib treatment in head and neck cancer patients.
참고문헌 (38)
- Forastiere AA, "Head and neck cancer", N Engl J Med, 345, pp.1890~1900 (2002)
- Kim ES, "Chemoprevention of aerodigestive tract cancer", Annu Rev Med, 53, pp.233~243 (2003)
- Shin DM, "Biomarkers in upper aerodigestive tract tumorigenesis: a review", Cancer Epidemiol Biomark Prev, 3, pp.679~709 (1994)
- Jefferies S, "Genetic mechanisms in squamous cell carcinoma of the head and neck", Oral Oncol, 37, pp.115~126 (2001)
- Boyle WJ, "Growth factor and tyrosine kinase receptors during development and cancer", Curr Opin Oncol, 4, pp.156~162 (1992)
- Hu G, "Expression of epidermal growth factor receptor and human papillomavirus E6", E7proteins in cervical carcinoma cells, 1997, pp.89, 1271~1276
- Iihara K, "Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for autocrine proliferation", Cancer, 71, pp.2902~2909 (1993)
- Grandis JR, "Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival", J Natl Cancer Inst, 90, pp.824~832 (1998)
- Janmaat ML, "Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors", Oncologist, 8, pp.576~586 (2003)
- Grandis JR, "Signaling through the epidermal growth factor receptor during the development of malgnancy", Pharmacol Ther, 102, pp.37~46 (2004)
- Albanell J, "Activated extracellular signal- regulated kinases: association with epidermal growth factor receptor", transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments, 2001, pp.61, 6500~6510
- Gullick WJ, "The type I growth factoe receptors and their ligands considered as complex system", Endocrine Related Cancer, 8, pp.75~82 (2001)
- Yarden Y, "The EGFR family and its ligands in human cancer: Signaling mechanisms and therapeutic apportunities", Eur J Cancer, 37, pp.3~8 (2002)
- Lui VWY, "EGFR-mediated cell cycle regulation", Anticancer Res, 22, pp.1~12 (2002)
- Cowley GO, "The amount of EGF receptor is elevated on squamous cell carcinomas", Cancer Cells, 1, pp.5~10 (1984)
- Partridge M, "Expression of epidermal growth factor receptors on oral squamous cell carcinomas", Br J Oral Max Surg, 26, pp.381~386 (1988)
- Shin DM, "Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer", Clinical Cancer Res, 7, pp.1204~1213 (2001)
- Maurizio M, "Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma", Br J Cancer, 74, pp.1253~1257 (1996)
- Grandis JR, "Levels of TGFα, and EGFR protein in head and neck squamous cell carcinoma and patients survival", J Natl Cancer Inst, 90, pp.824~832 (1998)
- Maiorano E, "Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa", J Pathology, 185, pp.167~174 (2000)
- Magne N, "The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy", Eur J Cancer, 37, pp.2169~2177 (2001)
- Ang KK, "Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma", Cancer Res, 62, pp.7350~7356 (2002)
- Hoffmann TK, "Serum level and tissue expression of cerbB- 1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck", Oral Oncol, 37, pp.50~56 (2001)
- Khademi B, "The expression of p53, c-erbB-1 and c-erbB- 2 molecules and their correlation with prognostic markers in patients with head and neck tumors", Cancer Letters, 184, pp.223~230 (2002)
- O-charoenrat P, "The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma (Review)", Oral Oncology, 38, pp.627~640 (2002)
- Putti TC, "Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: A multicentre immunohistochemical study in the Asia-Pacific region", Histopathology, 41, pp.144~151 (2002)
- Haung SM, "Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinoma: Inhibition of damage repair, cell cycle kinetics and tumour angiogenesis", Clin Cancer Res, 6, pp.2166~2174 (2000)
- Liang K, "The epidermal growth factor receptor mediates radioresistance", Int J Radiation Biol Phys, 57, pp.246~254 (2003)
- Ang KK, "Epidermal growth factor receptor and response of head and neck carcinoma to therapy", Int J Radiation Oncology Biol Phys, 58, pp.959~965 (2004)
- Cohen EE, "Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck", J Clin Oncol, 21, pp.1980~1987 (2003)
- Cohen EE, "Phase II trial of gefitinib 250 mg daily in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck, 2005, pp.11, 8418~8424
- She QB, "The BAD protein integrates survival signaling by EGFR", MAPK and PI3K, Cancer Cell, pp.2005, 8[DOI]
- Sriuranpong V, "Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the interleukin 6", gp130 cytokine system, 2003, pp.63, 2948~2956
- Thompson S, "Epidermal to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenograft to epidermal growth factor receptor inhibition", Cancer Res, 65, pp.9455~9462 (2005)
- Yauch RL, "Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients", Clin Cancer Res, 11, pp.8686~8698 (2005)
- Spector NL, "Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies", J Clin Oncol, 23, pp.2502~2512 (2005)
- Noro R, "Seike M et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation", BMC Cancer, 6, pp.277~298 (2006)
- Cappuzzo F, "Bartolini S, Rossi E, Ludovini V, Gregorc V et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer", J Natl Cancer Inst, 96, pp.1133~1141 (2004)